18:26 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Audentes reports Phase I/II muscle biopsy data for myopathy gene therapy

Audentes Therapeutics Inc. (NASDAQ:BOLD) reported data from its 24-week muscle biopsy analyses of the first dose cohort and said an IDMC recommended proceeding to the second dose cohort of the Phase I/II ASPIRO trial evaluating...
17:43 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Imbruvica plus chemotherapy misses in Phase III for subtype of DLBCL

AbbVie Inc. (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) said Imbruvica ibrutinib plus R-CHOP chemotherapy missed the primary endpoint of improving event-free survival vs. placebo plus R-CHOP chemotherapy in the Phase III PHOENIX trial to treat...
22:57 , Jul 19, 2018 |  BC Extra  |  Preclinical News

Inhibiting EIF2AK1 could help treat sickle cell disease

Researchers from Children’s Hospital of Philadelphia and University of Pennsylvania showed that inhibiting EIF2AK1 to increase fetal hemoglobin could help treat sickle cell disease. As genetic diseases such as SCD and some thalassemias affect patients only...
19:29 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

CTI's Pixuvri fails in postapproval trial

CTI BioPharma Corp. (NASDAQ:CTIC) said Pixuvri pixantrone missed the primary endpoint in the postmarketing Phase III PIX306 trial to treat aggressive B-cell non-Hodgkin's lymphoma (NHL). The failure means PIX306 "has not met the specific obligations"...
16:53 , Jul 9, 2018 |  BC Extra  |  Clinical News

CTI's Pixuvri fails in postapproval trial

CTI BioPharma Corp. (NASDAQ:CTIC) said Pixuvri pixantrone missed the primary endpoint in the postmarketing Phase III PIX306 trial to treat aggressive B-cell non-Hodgkin's lymphoma (NHL). The failure means PIX306 "has not met the specific obligations"...
19:48 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

PTC's oral SMA candidate improves motor development scores in pivotal trial

PTC Therapeutics Inc. (NASDAQ:PTCT) reported updated interim data from part 1 of the pivotal Phase II/III FIREFISH trial showing that oral risdiplam (RG7916) improved motor development scores in infants with spinal muscular atrophy (SMA) type...
22:46 , Jun 18, 2018 |  BC Extra  |  Clinical News

PTC spikes on interim pivotal data for oral SMA candidate

PTC Therapeutics Inc. (NASDAQ:PTCT) gained $10.33 (28%) to $47.88 after reporting updated interim data from part 1 of the pivotal Phase II/III FIREFISH trial showing that oral risdiplam (RG7916) improved motor development scores in infants...
18:20 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Celgene reports detailed data from missed Phase III of Revlimid combo for follicular lymphoma

Celgene Corp. (NASDAQ:CELG) reported detailed data from the Phase III RELEVANCE trial of Revlimid lenalidomide plus Rituxan rituximab to treat previously untreated follicular lymphoma. The data were presented at the American Society of Clinical Oncology...
20:35 , Jun 6, 2018 |  BC Innovations  |  Translation in Brief

Distinguishing DLBCL

A genomics-based method of subtyping diffuse large B cell lymphoma could improve prognostic predictions and identification of subtype-appropriate treatment regimens. Diffuse large B cell lymphoma (DLBCL) is clinically and genetically heterogeneous and roughly 40% of patients...
15:32 , May 25, 2018 |  BC Week In Review  |  Clinical News

Audentes reports updated Phase I/II myopathy data for AT132

Audentes Therapeutics Inc. (NASDAQ:BOLD) reported updated interim data from the first cohort of the open-label, dose-escalation, U.S. Phase I/II ASPIRO trial testing AT132 in patients with X-linked myotubular myopathy (XLMTM). The presentation at the American...